Principles and Practice of Fertility Preservation: Basic cancer biology and immunology

[1]  M. Bishop,et al.  Immunotherapy for breast cancer. , 2017, Cancer chemotherapy and biological response modifiers.

[2]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[3]  Ming-Tsang Wu,et al.  Association between Helicobacter pylori seropositivity and digestive tract cancers. , 2009, World journal of gastroenterology.

[4]  R. Vonderheide,et al.  Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells , 2009, Annals of the New York Academy of Sciences.

[5]  S. Quezada,et al.  Cancer immunotherapy: co‐stimulatory agonists and co‐inhibitory antagonists , 2009, Clinical and experimental immunology.

[6]  T. Cotter,et al.  Apoptosis and cancer: the genesis of a research field , 2009, Nature Reviews Cancer.

[7]  G. Dore,et al.  Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden , 2009, Journal of viral hepatitis.

[8]  Robert A. Weinberg,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[9]  Daniel Nowak,et al.  Differentiation therapy of leukemia: 3 decades of development. , 2009, Blood.

[10]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[11]  I. Tannock,et al.  Cytokines and their relationship to the symptoms and outcome of cancer , 2008, Nature Reviews Cancer.

[12]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[13]  W. Birchmeier,et al.  Wnt signalling and its impact on development and cancer , 2008, Nature Reviews Cancer.

[14]  B. Nelson,et al.  The impact of T‐cell immunity on ovarian cancer outcomes , 2008, Immunological reviews.

[15]  A. Ashworth,et al.  DNA repair deficiency as a therapeutic target in cancer. , 2008, Current opinion in genetics & development.

[16]  Manuel Serrano,et al.  The common biology of cancer and ageing , 2007, Nature.

[17]  C. Goodnow.  Multistep Pathogenesis of Autoimmune Disease , 2007, Cell.

[18]  C. June,et al.  Adoptive T cell therapy for cancer in the clinic. , 2007, The Journal of clinical investigation.

[19]  S. Eccles,et al.  Metastasis: recent discoveries and novel treatment strategies , 2007, The Lancet.

[20]  M. Smyth,et al.  Immune surveillance of tumors. , 2007, The Journal of clinical investigation.

[21]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[22]  E. Gilboa.  DC-based cancer vaccines. , 2007, The Journal of clinical investigation.

[23]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[24]  C. June,et al.  Principles of adoptive T cell cancer therapy. , 2007, The Journal of clinical investigation.

[25]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[26]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[27]  A. Baldwin,et al.  Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression , 2006, Oncogene.

[28]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[29]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[30]  Jiri Zavadil,et al.  TGF-β and epithelial-to-mesenchymal transitions , 2005, Oncogene.

[31]  A. Mauviel,et al.  Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-β: implications for carcinogenesis , 2005, Oncogene.

[32]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[33]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[34]  E. Mitchell,et al.  Carcinoembryonic Antigen in the Staging and Follow-up of Patients with Colorectal Cancer , 2005, Cancer investigation.

[35]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[36]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[37]  G. Pawelec.  Tumour escape from the immune response , 2004, Cancer Immunology, Immunotherapy.

[38]  G. Pawelec.  Immunotherapy and immunoselection – tumour escape as the final hurdle , 2004, FEBS letters.

[39]  S. Rosenberg,et al.  T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product , 2004, The Journal of Immunology.

[40]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[41]  D. Harrison,et al.  The JAK/STAT signaling pathway , 2004, Journal of Cell Science.

[42]  G. Pawelec.  Tumour escape: antitumour effectors too much of a good thing? , 2004, Cancer Immunology, Immunotherapy.

[43]  Marina Pasca di Magliano,et al.  Hedgehog signalling in cancer formation and maintenance , 2003, Nature Reviews Cancer.

[44]  G. Weiner,et al.  CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response , 2003, Current opinion in oncology.

[45]  K. Vermeulen,et al.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer , 2003, Cell proliferation.

[46]  R. Reddel.  Alternative lengthening of telomeres, telomerase, and cancer. , 2003, Cancer letters.

[47]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Eilers,et al.  Transcriptional repression by Myc. , 2003, Trends in cell biology.

[49]  J. Xiang,et al.  Advances in dendritic cell-based vaccine of cancer. , 2002, Cancer biotherapy & radiopharmaceuticals.

[50]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[51]  Alfonso Bellacosa,et al.  Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.

[52]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[53]  J. Aster,et al.  Notch Signaling in Cancer , 2002, Cancer biology & therapy.

[54]  David A Jones,et al.  Reactivating the expression of methylation silenced genes in human cancer , 2002, Oncogene.

[55]  J. Massagué,et al.  E2F4/5 and p107 as Smad Cofactors Linking the TGFβ Receptor to c-myc Repression , 2002, Cell.

[56]  S. Weitzman,et al.  Chronic inflammation and cancer. , 2002, Oncology.

[57]  P. Shapiro.  Ras-MAP Kinase Signaling Pathways and Control of Cell Proliferation: Relevance to Cancer Therapy , 2002, Critical reviews in clinical laboratory sciences.

[58]  M. Eilers,et al.  Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. , 2001, Genes & development.

[59]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[60]  R. Weinberg,et al.  Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. , 2001, Experimental cell research.

[61]  J. Hoeijmakers,et al.  Chromosomal stability and the DNA double-stranded break connection , 2001, Nature Reviews Genetics.

[62]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[63]  J. Butel,et al.  Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. , 2000, Carcinogenesis.

[64]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[65]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[66]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[67]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[68]  Paul Polakis,et al.  Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly , 1996, Science.

[69]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[70]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[71]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[72]  A. Burgess,et al.  Regulation of the ras signalling network , 1994, BioEssays : news and reviews in molecular, cellular and developmental biology.

[73]  R. Weinberg,et al.  Tumor suppressor genes. , 1991, Science.

[74]  Christine Chomienne,et al.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.

[75]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[76]  C. Daniel,et al.  Reversible inhibition of mammary gland growth by transforming growth factor-beta. , 1987, Science.

[77]  R. Weinberg,et al.  Cellular oncogenes and multistep carcinogenesis. , 1983, Science.

[78]  R. Weinberg,et al.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts , 1981, Nature.

[79]  J. Rowley,et al.  Further evidence for a non‐random chromosomal abnormality in acute promyelocytic leukemia , 1977, International journal of cancer.

[80]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[81]  M. Burnet.  IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS. , 1964, British medical bulletin.

[82]  B. Mcclintock,et al.  The Stability of Broken Ends of Chromosomes in Zea Mays. , 1941, Genetics.

[83]  W. Coley,et al.  THE TREATMENT OF MALIGNAT TUMORS BY REPEATED INOCULATIONS OF ERYSIPELAS: WITH A REPORT OF TEN ORIGINAL CASES , 1893 .

[84]  M. Barbacid,et al.  Milestones in cell division: To cycle or not to cycle: a critical decision in cancer , 2001, Nature Reviews Cancer.

[85]  Y. Tsujimoto,et al.  Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. , 1987, Oncogene.

[86]  Watkins Jf.  Proceedings: Genetics and the cancer cell: cell fusion in the study of tumor cells. , 1971 .